A Phase 1, Double-Blind, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Single-Vial Lyophilized ID93 + GLA-SE Vaccine Administered Intramuscularly in Healthy Adult Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs ID 93 (Primary)
- Indications Pulmonary tuberculosis
- Focus Adverse reactions
- 29 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 07 Nov 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 22 Oct 2018 to 1 Nov 2018.
- 06 Nov 2018 New trial record